Literature DB >> 10857953

Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen.

A Mohn, S Strang, K Wernicke-Panten, A M Lang, J A Edge, D B Dunger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10857953     DOI： 10.2337/diacare.23.4.557a

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  7 in total

1.  Long-acting basal insulin analogs: latest developments and clinical usefulness.

Authors:  Anastasia N Mavrogiannaki; Ilias N Migdalis
Journal:  Ther Adv Chronic Dis       Date:  2012-11       Impact factor: 5.091

2.  From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a 'routine' diabetes clinic?

Authors:  L A Distiller; B I Joffe
Journal:  Diabetologia       Date:  2006-09-19       Impact factor: 10.122

Review 3.  Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus.

Authors:  K McKeage; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus.

Authors:  Harriet L Miles; Carlo L Acerini
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

5.  (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.

Authors:  Bianca Hemmingsen; Maria-Inti Metzendorf; Bernd Richter
Journal:  Cochrane Database Syst Rev       Date:  2021-03-04

6.  Insulin glargine in pediatric patients with type 1 diabetes in Japan.

Authors:  Tatsuhiko Urakami; Yusuke Naito; Yutaka Seino
Journal:  Pediatr Int       Date:  2014-09-16       Impact factor: 1.524

7.  A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus.

Authors:  Min Liu; Zhiguang Zhou; Jinhua Yan; Pin Li; Wenhui Song; Junfen Fu; Xiaobo Chen; Weigang Zhao; Li Xi; Xiaoping Luo; Liang Sha; Xueyuan Deng; Chunxiu Gong
Journal:  BMC Endocr Disord       Date:  2016-11-26       Impact factor: 2.763
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.